JP2019502360A5 - - Google Patents

Download PDF

Info

Publication number
JP2019502360A5
JP2019502360A5 JP2018516122A JP2018516122A JP2019502360A5 JP 2019502360 A5 JP2019502360 A5 JP 2019502360A5 JP 2018516122 A JP2018516122 A JP 2018516122A JP 2018516122 A JP2018516122 A JP 2018516122A JP 2019502360 A5 JP2019502360 A5 JP 2019502360A5
Authority
JP
Japan
Prior art keywords
seq
peptide
cell
nos
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516122A
Other languages
English (en)
Japanese (ja)
Other versions
JP7053457B2 (ja
JP2019502360A (ja
Filing date
Publication date
Priority claimed from GBGB1521746.6A external-priority patent/GB201521746D0/en
Application filed filed Critical
Publication of JP2019502360A publication Critical patent/JP2019502360A/ja
Publication of JP2019502360A5 publication Critical patent/JP2019502360A5/ja
Priority to JP2021201297A priority Critical patent/JP2022058349A/ja
Application granted granted Critical
Publication of JP7053457B2 publication Critical patent/JP7053457B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516122A 2015-12-10 2016-11-24 Cllおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ Expired - Fee Related JP7053457B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021201297A JP2022058349A (ja) 2015-12-10 2021-12-11 Cllおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562265615P 2015-12-10 2015-12-10
US62/265,615 2015-12-10
GBGB1521746.6A GB201521746D0 (en) 2015-12-10 2015-12-10 Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB1521746.6 2015-12-10
PCT/EP2016/078718 WO2017097602A1 (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021201297A Division JP2022058349A (ja) 2015-12-10 2021-12-11 Cllおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Publications (3)

Publication Number Publication Date
JP2019502360A JP2019502360A (ja) 2019-01-31
JP2019502360A5 true JP2019502360A5 (https=) 2020-01-30
JP7053457B2 JP7053457B2 (ja) 2022-04-12

Family

ID=55274485

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018516122A Expired - Fee Related JP7053457B2 (ja) 2015-12-10 2016-11-24 Cllおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2021201297A Pending JP2022058349A (ja) 2015-12-10 2021-12-11 Cllおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021201297A Pending JP2022058349A (ja) 2015-12-10 2021-12-11 Cllおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Country Status (25)

Country Link
US (14) US10117916B2 (https=)
EP (1) EP3387008A1 (https=)
JP (2) JP7053457B2 (https=)
KR (1) KR20180086190A (https=)
CN (1) CN108602867A (https=)
AR (1) AR106920A1 (https=)
AU (3) AU2016368981B2 (https=)
BR (1) BR112018007206A2 (https=)
CA (1) CA3005813A1 (https=)
CL (6) CL2018001532A1 (https=)
CO (1) CO2018004865A2 (https=)
CR (6) CR20180295A (https=)
EA (1) EA201891074A1 (https=)
GB (1) GB201521746D0 (https=)
HK (1) HK1259376A1 (https=)
IL (1) IL259304A (https=)
MA (2) MA42072A1 (https=)
MX (1) MX2018005372A (https=)
PE (1) PE20181075A1 (https=)
PH (1) PH12018500848A1 (https=)
SG (3) SG11201801670YA (https=)
TW (2) TWI658050B (https=)
UA (1) UA124575C2 (https=)
WO (1) WO2017097602A1 (https=)
ZA (1) ZA201801752B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173560A1 (en) 2020-02-24 2021-09-02 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
MY197772A (en) 2017-04-10 2023-07-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108079285B (zh) * 2018-02-06 2021-01-01 昆明龙津药业股份有限公司 用于蛇毒酶制剂的门冬氨酸稳定剂及制备方法
EP3749753B1 (en) 2018-02-09 2025-04-02 Immatics US, Inc. Methods for manufacturing t cells
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
MX2021015033A (es) 2019-06-06 2022-01-18 Immatics Biotechnologies Gmbh Clasificacion con contraseleccion utilizando peptidos de secuencias similares.
JP7834016B2 (ja) * 2019-07-05 2026-03-23 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230158132A1 (en) * 2020-04-14 2023-05-25 Universite De Montreal Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof
EP3907284A1 (en) * 2020-05-06 2021-11-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against hematologic neoplasms and other cancers
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離cd8+選擇t細胞的方法
KR20230135589A (ko) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 Cd8 폴리펩타이드, 조성물 및 이의 사용 방법
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス,アイエヌシー. 条件付きリガンド交換により産生されたペプチドmhc複合体を使用する免疫細胞の選択
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於t細胞療法之t細胞群體的單核球耗盡
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス,アイエヌシー. 膜結合型il-15、cd8ポリペプチド、細胞、組成物、およびそれらの使用方法
JP2025515603A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス,アイエヌシー. Il-12ポリペプチド、il-15ポリペプチド、il-18ポリペプチド、cd8ポリペプチド、それらの組成物、およびそれらの使用方法
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス,アイエヌシー. ドミナントネガティブTGFβ受容体ポリペプチド、CD8ポリペプチド、細胞、組成物、およびその使用方法
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2024223849A1 (en) * 2023-04-27 2024-10-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Neoepitope immunogenic peptides for cancer treatment and diagnosis
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026033136A1 (en) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Advanced treatment modalities for anti-prame tcr-engineered immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU706443B2 (en) 1994-04-22 1999-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Melanoma antigens
US20040005561A1 (en) * 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20040000556A1 (en) * 2003-01-25 2004-01-01 Harris Jennifer Hope Trash receptacles that use plastic grocery bags as liners and methods of advertising
EP1627076A4 (en) 2003-03-14 2008-07-02 Ppd Biomarker Discovery Scienc BIOLOGICAL MARKERS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
JP2007519910A (ja) * 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
WO2012079878A2 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2007103770A2 (en) 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2011502484A (ja) * 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Hla−dr結合性ペプチドおよびそれらの使用
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
US20110151494A1 (en) 2008-06-30 2011-06-23 H. Lee Moffit Cancer & Research Institute Methods and materials for monitoring myeloma using quantitative mass spectrometry
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027311A2 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
EP2330122A1 (en) * 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP derived modified peptide
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2013019634A1 (en) 2011-07-29 2013-02-07 University Of Georgia Research Foundation, Inc. Alpha toxin detection of gpi anchored proteins
WO2013037972A1 (en) * 2011-09-16 2013-03-21 Pamgene B.V. Method for predicting response to endocrine therapy
EP3639831A1 (en) * 2012-08-15 2020-04-22 Université de Montréal Method for identifying novel minor histocompatibility antigens
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二)
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108026154B (zh) * 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers

Similar Documents

Publication Publication Date Title
JP2019502360A5 (https=)
JP2019506838A5 (https=)
JP2019510465A5 (https=)
JP2021168652A5 (https=)
JP2018529320A5 (https=)
JP2018510628A5 (https=)
JP2018536383A5 (https=)
JP2019511214A5 (https=)
JP2018511321A5 (https=)
JP2018520653A5 (https=)
JP2018519243A5 (https=)
JP2018518937A5 (https=)
JP2018509135A5 (https=)
JP2021514178A5 (https=)
JP2024041841A5 (https=)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2024099580A5 (https=)
JP2018521641A5 (https=)
JP2017525336A5 (https=)
JP2018518956A5 (https=)
JP2021535900A5 (https=)
JP2017502076A5 (https=)
JP2020530759A5 (https=)
JP2017524337A5 (https=)
JP2019516663A5 (https=)